Neuro-critical care   

Questions discussed in this category


What is the cost and accessibility of CYP2C19 gene testing? Does the limited availability of rapid genotyping techniques limit the clinical applicabil...

How do you plan to incorporate the results of the CHANCE-2 trial (Wang et al., PMID 34708996) in your own practice?

For instance, if the patient doesn’t tolerate apnea testing, is too unstable to go for ancillary testing outside the ICU, and TCDs/EEG are unava...

Is there any benefit to starting hyperosmolar therapy prior to the development of depressed level of consciousness or midline shift?


Papers discussed in this category


Neurotherapeutics,

The Lancet. Neurology, 2016-05

JAMA,

Contemp Neurol Ser,

N Engl J Med, 2021 Oct 28

The New England journal of medicine, 2018-07-19

N Engl J Med, 2013 Jun 26

N Engl J Med,